Vimarsana
Biggest News Aggregation in the World

Page 3 - Synact Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Synact Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Synact Pharma Today - Breaking & Trending Today

Rheumatoid Arthritis Market is Expected to Showcase Significant Growth in the 7MM at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Predicts DelveInsight - Vimarsana News

Rheumatoid Arthritis Market is Expected to Showcase Significant Growth in the 7MM at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Predicts DelveInsight

/PRNewswire/ -- DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid...

New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles - Vimarsana News

New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles

/PRNewswire/ -- DelveInsight's 'Rheumatoid Arthritis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

SynAct Pharma AB announces positive data from a Phase 2a trial of AP1189 in Covid-19 infected patients - The William Harvey Research Institute - Vimarsana News

SynAct Pharma AB announces positive data from a Phase 2a trial of AP1189 in Covid-19 infected patients - The William Harvey Research Institute

SynAct Pharma AB announces positive data from a Phase 2a trial of AP1189 in Covid-19 infected patients SynAct Pharma AB (“SynAct”) has just announced topline results from the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency.  Patients treated with 100mg AP1189 orally once-daily for 2-weeks achieved respiratory recovery (time to normalization of oxygen saturation on ambient air) on average 3.5 days (35%) quicker than placebo treated patients (6.4 days and 9.9 days on average respectively). Data from this exploratory pilot clinical trial support...

Source: qmul.ac.uk
SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients - Vimarsana News

SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients

Sponsrat Sponsrat SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients SynAct Pharma AB ("SynAct") today announced that dosing in part 2 of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been completed. The study is a randomized double-blind placebo-controlled study in 54 Covid-19 patients at clinical sites at Universidade Federal de Minas, Belo Horizonte, Brazil. Uppdaterad 2021-06-01 Publicer...

Source: realtid.se
Synact Pharma to present at upcoming investor conference - Vimarsana News

Synact Pharma to present at upcoming investor conference

Uppdaterad 2021-05-21 Publicerad 2021-05-21 Synact Pharma, today announces that members of its executive management team is invited to present at upcoming conference.: ABGSC Life Science Summit, virtual Date: 25 May 2021 Time: 09.30 CET

Source: realtid.se